Hospitals awaiting regulator’s guidance over Ranbaxy drugs

Hospitals awaiting regulator’s guidance over Ranbaxy drugs

Ranbaxy was asked to pay $500 mn to settle US govt charges of selling adulterated drugs.

Leading hospitals in Mumbai are awaiting guidance from the regulator Food and Drug Administration before taking any decision on issuing advisory over prescribing drugs manufactured by Ranbaxy.

“FDA is the regulatory authority here and unless it tells us,we will not do anything … (issue advisory) over prescribing Ranbaxy drugs,” Hinduja Hospital Director

Professional Services Dr Gustad Daver said.

Earlier,Jaslok Hospital in Mumbai had issued an advisory to its doctors to avoid prescribing drugs manufactured by Ranbaxy.

Apollo Pharmacy,India’s largest pharmacy chain,has also issued ‘cautionary’ advisory based on concerns raised by the medical committee last week.


Leading hospitals in Mumbai like Kokilaben Hospital,KEM Hospital,Nanavati and Bombay Hospital have continued to prescribe the Ranbaxy drugs.

On May 13,Ranbaxy was asked to pay USD 500 million to settle the US government charges of selling adulterated drugs manufactured at its two plants in India.

The Indian Medical Association has asked the Drug Controller General of India to investigate the quality of drugs manufactured and sold by Ranbaxy.

Ranbaxy Laboratories is an integrated international pharmaceuticals company engaged in the marketing,production and distribution of pharmaceuticals products.

It manufactures medicines for cardiovascular,respiratory and gastro-intestinal ailments,besides anti-retroviral drugs.